Trials / Completed
CompletedNCT04675151
Safety and Efficacy of Nyxol With Pilocarpine Eye Drops in Subjects With Presbyopia
Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) With Pilocarpine Eye Drops in Subjects With Presbyopia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 150 (actual)
- Sponsor
- Ocuphire Pharma, Inc. · Industry
- Sex
- All
- Age
- 40 Years – 64 Years
- Healthy volunteers
- Not accepted
Summary
The objectives of this study are: To evaluate the efficacy of Nyxol + Pilocarpine to improve DCNVA in subjects with presbyopia
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Phentolamine Ophthalmic Solution 0.75% | 0.75% phentolamine ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist |
| DRUG | Pilocarpine | Pilocarpine ophthalmic solution |
| OTHER | Placebo | Topical sterile ophthalmic solution |
Timeline
- Start date
- 2021-02-15
- Primary completion
- 2021-05-17
- Completion
- 2021-06-30
- First posted
- 2020-12-19
- Last updated
- 2025-10-10
- Results posted
- 2023-08-02
Locations
17 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04675151. Inclusion in this directory is not an endorsement.